Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study evaluating GlaxoSmithKline's meningococcal vaccine with or without co-administration of Cervarix and Boostrix in female …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)
• Cervarix (human papillomavirus vaccine, bivalent)
• Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-07-03